The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.
50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.
Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.
Wondfo Dry Chemistry Analyzer can test 16 items and provide the result within 2 minutes, ideal for the detection of cardiac markers, kidney function, liver function, pancreatitis, etc.
Ready-to-use lyophilized RT-PCR Reagent；
Gold Standard for COVID-19 Diagnosis
Home/News & Press/Wondfo News/Statement from Wondfo Biotech, following the Central Drugs Standard Control Organisation decision
Statement from Wondfo Biotech, following the Central Drugs Standard Control Organisation decision
May 01,2020 (Edit) Wondfo
It is with regret that we read the notice from the Central Drugs Standard Control Organisation (CDSCO) of India to cancel the import license granted to Wondfo SARS-CoV-2 Antibody Test (Lateral Flow Method).
Since the Indian Council of Medial Research (ICMR) issued the ‘Advisory on Rapid Antibody Blood Tests’ on April 27th, 2020, we have asked ICMR for more information to better understand the issue. We are disappointed that we have not received a response from the organization to date.
Our business continues with the strength, determination and collective effort the global pandemic requires.
Quality is always our first priority. Wondfo has been and will continue to be transparent about the measures we are taking to ensure the supply and accuracy of our tests and that our products meet the needs of countries as we collectively combat COVID-19.
The first developed technology platform with various application scenarios, including infectious disease, fertility, DOA, etc.
50+ kinds of reagents and five high-performance devices, focusing on detecting cardiovascular disease, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and others.
Single-dose Chemiluminescense Immunoassay Platform
Wondfo optical blood coagulation analyzer is the first one in the world that can test PT, APTT, TT, FIB, and ACT simultaneously.
Our Blood Gas Analyzer BGA-102 can produce the result in 30s. Its advantages of portability, easy operation, durability, and high performance make it ideal for clinics, laboratories, and hospitals.
Wondfo Dry Chemistry Analyzer can test 16 items and provide the result within 2 minutes, ideal for the detection of cardiac markers, kidney function, liver function, pancreatitis, etc.
Ready-to-use lyophilized RT-PCR Reagent；
Wondfo PA-3600 IHC Staining System
Advanced rapid diagnostic test with WHO prequalification for infectious disease
The Future Intelligent Medical Assistant to Healthcare
Fight against the pandemic through continuous innovation
